Report of Friends of User Rights 2021 – Online Expert Meeting, 6–9 July 2021

2021 ◽  
Keyword(s):  
Expert Meeting

Posttransplant CMV infection and the role of immunosuppression (Sponsor: Novartis Pharma GmbH, Nürnberg)

2016 ◽  
Vol 04 (01) ◽  
pp. 4-10
Keyword(s):  
Lower Incidence ◽  
Paradigm Shift ◽  
Mtor Inhibitor ◽  
De Novo ◽  
Expert Panel ◽  
Risk Of Infection ◽  
Cmv Infection ◽  
Expert Meeting ◽  
Selection Of

AbstractImmunosuppression permits graft survival after transplantation and consequently a longer and better life. On the other hand, it increases the risk of infection, for instance with cytomegalovirus (CMV). However, the various available immunosuppressive therapies differ in this regard. One of the first clinical trials using de novo everolimus after kidney transplantation [1] already revealed a considerably lower incidence of CMV infection in the everolimus arms than in the mycophenolate mofetil (MMF) arm. This result was repeatedly confirmed in later studies [2–4]. Everolimus is now considered a substance with antiviral properties. This article is based on the expert meeting “Posttransplant CMV infection and the role of immunosuppression”. The expert panel called for a paradigm shift: In a CMV prevention strategy the targeted selection of the immunosuppressive therapy is also a key element. For patients with elevated risk of CMV, mTOR inhibitor-based immunosuppression is advantageous as it is associated with a significantly lower incidence of CMV events.

First international new technologies and expert meeting

Obésité ◽  
2015 ◽  
Vol 10 (4) ◽  
pp. 283-292
Author(s):  
J. Dargent
Keyword(s):  
New Technologies ◽  
Expert Meeting

scholarly journals Introduction

2012 ◽  
Vol 24 (S1) ◽  
pp. S1-S2 ◽  
Author(s):  
Seol-Heui Han ◽  
Helen Lavretsky
Keyword(s):  
Cognitive Decline ◽  
Ginkgo Biloba ◽  
Symptomatic Treatment ◽  
Egb 761 ◽  
Target Populations ◽  
Age Related ◽  
Expert Meeting ◽  
Recent Developments ◽  
Study Designs ◽  
Age Related Cognitive Decline

In June 2011, Dr. Willmar Schwabe Pharmaceuticals sponsored a two-day expert meeting in Amsterdam, The Netherlands. The meeting brought together 19 dementia experts from a range of disciplines and countries to review preclinical and clinical data on Ginkgo biloba special extract EGb 761® in the context of recent developments in the diagnosis and treatment of age-related cognitive decline and Alzheimer's disease (AD). Ginkgo biloba special extract EGb 761® is formally approved and reimbursed for the symptomatic treatment of age-related cognitive decline or dementia by numerous authorities worldwide. The meeting therefore focused on relevant research questions and potential study designs with appropriate target populations to prove the efficacy of Ginkgo biloba special extract EGb 761® as a disease-modifying product in AD and to reveal further relevant modes of action.

Sign in / Sign up

Export Citation Format

Share Document